Inovio Pharmaceuticals Inc. (INO) News
Filter INO News Items
INO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest INO News From Around the Web
Below are the latest news stories about INOVIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INO as an investment opportunity.
The 3 Most Undervalued Biotech Stocks to Buy: November 2023Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call TranscriptInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS, expectations were $-0.13. Operator: Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financial Results Conference Call. At this time all lines are in a listen-only […] |
Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call TranscriptGood afternoon, and thank you for joining the Inovio 2023 third quarter conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO; Dr. Michael Sumner, chief medical officer; Mr. |
INOVIO Reports Third Quarter 2023 Financial Results and Operational HighlightsINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. |
INOVIO Reports Inducement Grants Under Inducement PlanINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). |
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. |
Inovio Pharma (INO) Stock Surges 19% This Month: Here's WhyInovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA. |
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval ProgramINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program. The FDA also advised that the |
Inovio spinoff Geneos raises another $5M to advance therapeutic cancer vaccinesA Montgomery County biotherapeutics company developing personalized therapeutic cancer vaccines said Thursday it has completed its series A3 financing round with an additional investment of $5 million. Geneos Therapeutics of Plymouth Meeting has now raised a total of $10 million from the round, and more than $36 million since its inception. The new investment adds Shanghai Healthcare Capital, a private equity firm based in China, to the company's investor syndicate. |
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 MillionGeneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million. This investment adds Shanghai Healthcare Capital (SHC) to Geneos' investor syndicate. Dr. Jing Bao will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials. |